

Info Sheet for Technical description

No. XXXX (事務局付番)

Organization

* Mandatoty fields

Name of Organization*	Cyfuse Biomedical K.K.	
Address, City, States, Zip, Country*	West Wing-1F, Sumitomo Fudosan Mita Twin Bldg. 3-5-27, Mita, Minato-ku, Tokyo	
URL	www.cyfusebio.com	
Brief Descriptions of Organization* (Approx. 100 words)	<p>Since its establishment in 2010, Cyfuse has been in business with the mission of making social contributions in the medical field, including regenerative medicine and drug discovery, by fabricating three-dimensional tissues and organs composed of "only cells."</p> <p>One of the goals of Cyfuse has been made to ensure that steric constructs created with the use of spheroids obtained via the phenomenon of cell aggregation and Bio 3D Printer is put to practical use as cellular products. We are also working on developing this Japanese technology on a global scale as well as becoming a leading company in regenerative medicine.</p>	
Contact address	Name*	Toshihiko Maekawa
	Department* / Position	Research and Development/General Manager
	E-mail* / TEL	toshihiko.maekawa@cyfusebm.com

What kind of technology do you want to offer? *

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**

* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
<input checked="" type="checkbox"/> Yes	If FIRM uses the presentation material, FIRM will ask Cyfuse for confirmation.
<input type="checkbox"/> No	

Filled in by*

Date*

Toshihiko Maekawa
2023/9/22

Info Sheet for Technical overview
--

No. XXXX (事務局付番)

* Mandatoty fields

Title*

Bio 3D printling technology

Category*

- | | | |
|---|---|---|
| <input type="checkbox"/> Facilities | <input checked="" type="checkbox"/> Manufacturing equipment | <input type="checkbox"/> Inspection equipment |
| <input type="checkbox"/> Cells | <input type="checkbox"/> Culture medium | <input type="checkbox"/> Reagents |
| <input type="checkbox"/> Cell banking | <input type="checkbox"/> Storage / Container | <input type="checkbox"/> Logistics |
| <input type="checkbox"/> Cell / Viral vector manufacturing technology | | |

Description*

<p>A Bio 3D Printer robot performs three-dimensional modeling by stacking multiple layers of cell clusters called “spheroids,” which are formed due to the inherent self-aggregating capacity possessed by cells, on needle arrays according to a 3D design read by dedicated software.</p> <p>After the spheroids fuse together, they are removed from the needle arrays, creating a three-dimensional structure consisting solely of cells.</p> <p>The structure is then completed in the form of tissue or an organ (3D cellular product) that is equipped with functions allowing it to be used in transplant and research applications. Our Bio 3D printers are sold worldwide.</p>
--

Filled in by***Date***

Toshihiko Maekawa

2023/9/22